nodes	percent_of_prediction	percent_of_DWPC	metapath
Clodronate—PTGS2—Thalidomide—leprosy	0.427	0.556	CbGbCtD
Clodronate—PTGS2—Dapsone—leprosy	0.342	0.444	CbGbCtD
Clodronate—SLC25A4—peripheral nervous system—leprosy	0.0239	0.19	CbGeAlD
Clodronate—Acute myeloid leukaemia—Thalidomide—leprosy	0.0146	0.144	CcSEcCtD
Clodronate—SLC25A6—eye—leprosy	0.00954	0.076	CbGeAlD
Clodronate—Acute leukaemia—Thalidomide—leprosy	0.00837	0.0825	CcSEcCtD
Clodronate—SLC25A6—skin of body—leprosy	0.0083	0.0661	CbGeAlD
Clodronate—SLC25A5—eye—leprosy	0.0083	0.0661	CbGeAlD
Clodronate—SLC25A4—eye—leprosy	0.00778	0.062	CbGeAlD
Clodronate—SLC25A5—skin of body—leprosy	0.00722	0.0575	CbGeAlD
Clodronate—PTGS2—hindlimb—leprosy	0.00615	0.049	CbGeAlD
Clodronate—SLC25A5—tendon—leprosy	0.0055	0.0438	CbGeAlD
Clodronate—Proteinuria—Dapsone—leprosy	0.00532	0.0524	CcSEcCtD
Clodronate—PTGS2—appendage—leprosy	0.00528	0.042	CbGeAlD
Clodronate—Protein urine present—Dapsone—leprosy	0.00525	0.0517	CcSEcCtD
Clodronate—SLC25A6—testis—leprosy	0.00523	0.0417	CbGeAlD
Clodronate—SLC25A4—tendon—leprosy	0.00515	0.041	CbGeAlD
Clodronate—SLC25A6—nervous system—leprosy	0.00514	0.0409	CbGeAlD
Clodronate—SLC25A5—testis—leprosy	0.00455	0.0363	CbGeAlD
Clodronate—SLC25A5—nervous system—leprosy	0.00447	0.0356	CbGeAlD
Clodronate—PTGS2—skin epidermis—leprosy	0.00439	0.035	CbGeAlD
Clodronate—SLC25A4—testis—leprosy	0.00427	0.034	CbGeAlD
Clodronate—Foetor hepaticus—Thalidomide—leprosy	0.00422	0.0416	CcSEcCtD
Clodronate—SLC25A4—nervous system—leprosy	0.00419	0.0334	CbGeAlD
Clodronate—Serum creatinine increased—Thalidomide—leprosy	0.00389	0.0383	CcSEcCtD
Clodronate—Liver disorder—Thalidomide—leprosy	0.00351	0.0346	CcSEcCtD
Clodronate—Hypercalcaemia—Thalidomide—leprosy	0.00344	0.0339	CcSEcCtD
Clodronate—PTGS2—blood vessel—leprosy	0.00294	0.0234	CbGeAlD
Clodronate—Proteinuria—Thalidomide—leprosy	0.00272	0.0268	CcSEcCtD
Clodronate—Protein urine present—Thalidomide—leprosy	0.00269	0.0265	CcSEcCtD
Clodronate—Hypocalcaemia—Thalidomide—leprosy	0.00261	0.0258	CcSEcCtD
Clodronate—Oliguria—Thalidomide—leprosy	0.0026	0.0256	CcSEcCtD
Clodronate—Creatinine increased—Thalidomide—leprosy	0.00251	0.0248	CcSEcCtD
Clodronate—Hepatocellular injury—Thalidomide—leprosy	0.00239	0.0236	CcSEcCtD
Clodronate—Pharyngitis—Dapsone—leprosy	0.00233	0.023	CcSEcCtD
Clodronate—Renal failure acute—Thalidomide—leprosy	0.00188	0.0185	CcSEcCtD
Clodronate—Cardiac failure—Thalidomide—leprosy	0.00178	0.0175	CcSEcCtD
Clodronate—Blood creatinine increased—Thalidomide—leprosy	0.00163	0.016	CcSEcCtD
Clodronate—Dehydration—Thalidomide—leprosy	0.00162	0.0159	CcSEcCtD
Clodronate—Alanine aminotransferase increased—Thalidomide—leprosy	0.00153	0.0151	CcSEcCtD
Clodronate—Dysphagia—Thalidomide—leprosy	0.0015	0.0148	CcSEcCtD
Clodronate—Bronchospasm—Thalidomide—leprosy	0.00148	0.0146	CcSEcCtD
Clodronate—PTGS2—skin of body—leprosy	0.00136	0.0108	CbGeAlD
Clodronate—Pneumonia—Thalidomide—leprosy	0.00135	0.0133	CcSEcCtD
Clodronate—Abdominal pain—Dapsone—leprosy	0.00132	0.013	CcSEcCtD
Clodronate—Renal failure—Thalidomide—leprosy	0.00132	0.013	CcSEcCtD
Clodronate—Pharyngitis—Thalidomide—leprosy	0.00119	0.0118	CcSEcCtD
Clodronate—Urinary tract disorder—Thalidomide—leprosy	0.00119	0.0117	CcSEcCtD
Clodronate—Urethral disorder—Thalidomide—leprosy	0.00118	0.0116	CcSEcCtD
Clodronate—Mediastinal disorder—Thalidomide—leprosy	0.00108	0.0107	CcSEcCtD
Clodronate—Vomiting—Dapsone—leprosy	0.00106	0.0104	CcSEcCtD
Clodronate—PTGS2—tendon—leprosy	0.00104	0.00825	CbGeAlD
Clodronate—Nausea—Dapsone—leprosy	0.000991	0.00976	CcSEcCtD
Clodronate—Anaemia—Thalidomide—leprosy	0.000967	0.00953	CcSEcCtD
Clodronate—Angioedema—Thalidomide—leprosy	0.000956	0.00942	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Thalidomide—leprosy	0.000885	0.00872	CcSEcCtD
Clodronate—Infection—Thalidomide—leprosy	0.000848	0.00836	CcSEcCtD
Clodronate—PTGS2—nervous system—leprosy	0.000841	0.0067	CbGeAlD
Clodronate—Skin disorder—Thalidomide—leprosy	0.000829	0.00817	CcSEcCtD
Clodronate—Anorexia—Thalidomide—leprosy	0.000814	0.00802	CcSEcCtD
Clodronate—SLC25A5—Electron Transport Chain—SDHD—leprosy	0.000794	0.196	CbGpPWpGaD
Clodronate—Dyspnoea—Thalidomide—leprosy	0.000761	0.0075	CcSEcCtD
Clodronate—Dyspepsia—Thalidomide—leprosy	0.000752	0.00741	CcSEcCtD
Clodronate—Decreased appetite—Thalidomide—leprosy	0.000742	0.00731	CcSEcCtD
Clodronate—Gastrointestinal disorder—Thalidomide—leprosy	0.000737	0.00726	CcSEcCtD
Clodronate—Urticaria—Thalidomide—leprosy	0.000678	0.00668	CcSEcCtD
Clodronate—Abdominal pain—Thalidomide—leprosy	0.000675	0.00665	CcSEcCtD
Clodronate—SLC25A6—Electron Transport Chain—SDHD—leprosy	0.000666	0.164	CbGpPWpGaD
Clodronate—Pruritus—Thalidomide—leprosy	0.000604	0.00595	CcSEcCtD
Clodronate—Diarrhoea—Thalidomide—leprosy	0.000584	0.00576	CcSEcCtD
Clodronate—Vomiting—Thalidomide—leprosy	0.000543	0.00535	CcSEcCtD
Clodronate—Rash—Thalidomide—leprosy	0.000538	0.0053	CcSEcCtD
Clodronate—Dermatitis—Thalidomide—leprosy	0.000538	0.0053	CcSEcCtD
Clodronate—SLC25A4—Electron Transport Chain—SDHD—leprosy	0.00052	0.128	CbGpPWpGaD
Clodronate—Nausea—Thalidomide—leprosy	0.000507	0.005	CcSEcCtD
Clodronate—SLC25A5—Host Interactions of HIV factors—CD4—leprosy	0.000161	0.0397	CbGpPWpGaD
Clodronate—SLC25A4—SIDS Susceptibility Pathways—IL10—leprosy	0.000157	0.0386	CbGpPWpGaD
Clodronate—SLC25A6—Host Interactions of HIV factors—CD4—leprosy	0.000135	0.0333	CbGpPWpGaD
Clodronate—PTGS2—Calcium signaling in the CD4+ TCR pathway—CD40LG—leprosy	0.000119	0.0293	CbGpPWpGaD
Clodronate—SLC25A4—Host Interactions of HIV factors—CD4—leprosy	0.000105	0.026	CbGpPWpGaD
Clodronate—SLC25A5—HIV Infection—CD4—leprosy	0.000105	0.0258	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—SDHD—leprosy	9.01e-05	0.0222	CbGpPWpGaD
Clodronate—SLC25A6—HIV Infection—CD4—leprosy	8.78e-05	0.0216	CbGpPWpGaD
Clodronate—SLC25A5—Disease—SLC11A1—leprosy	8.09e-05	0.0199	CbGpPWpGaD
Clodronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—leprosy	7.69e-05	0.019	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—SDHD—leprosy	7.55e-05	0.0186	CbGpPWpGaD
Clodronate—PTGS2—Calcium signaling in the CD4+ TCR pathway—IFNG—leprosy	6.99e-05	0.0172	CbGpPWpGaD
Clodronate—SLC25A4—HIV Infection—CD4—leprosy	6.85e-05	0.0169	CbGpPWpGaD
Clodronate—SLC25A6—Disease—SLC11A1—leprosy	6.78e-05	0.0167	CbGpPWpGaD
Clodronate—PTGS2—Overview of nanoparticle effects—TNF—leprosy	6.35e-05	0.0156	CbGpPWpGaD
Clodronate—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—leprosy	6.21e-05	0.0153	CbGpPWpGaD
Clodronate—SLC25A4—SIDS Susceptibility Pathways—TNF—leprosy	5.96e-05	0.0147	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—SDHD—leprosy	5.9e-05	0.0145	CbGpPWpGaD
Clodronate—SLC25A4—Disease—SLC11A1—leprosy	5.29e-05	0.013	CbGpPWpGaD
Clodronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—leprosy	4.52e-05	0.0111	CbGpPWpGaD
Clodronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—leprosy	4.02e-05	0.00991	CbGpPWpGaD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—TNF—leprosy	3.13e-05	0.00771	CbGpPWpGaD
Clodronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—leprosy	2.93e-05	0.00722	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—CD4—leprosy	2.88e-05	0.00711	CbGpPWpGaD
Clodronate—PTGS2—Selenium Micronutrient Network—IFNG—leprosy	2.88e-05	0.00709	CbGpPWpGaD
Clodronate—SLC25A5—Disease—CD4—leprosy	2.57e-05	0.00633	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—IFNG—leprosy	2.28e-05	0.00561	CbGpPWpGaD
Clodronate—SLC25A6—Disease—CD4—leprosy	2.15e-05	0.0053	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—IL2—leprosy	2.02e-05	0.00498	CbGpPWpGaD
Clodronate—PTGS2—Selenium Micronutrient Network—TNF—leprosy	1.86e-05	0.00459	CbGpPWpGaD
Clodronate—SLC25A4—Disease—CD4—leprosy	1.68e-05	0.00414	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—TNF—leprosy	1.47e-05	0.00363	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—SDHD—leprosy	1.17e-05	0.00287	CbGpPWpGaD
Clodronate—PTGS2—Disease—SLC11A1—leprosy	1.05e-05	0.00258	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—leprosy	1e-05	0.00247	CbGpPWpGaD
Clodronate—PTGS2—Disease—CD4—leprosy	3.32e-06	0.000818	CbGpPWpGaD
